Literature DB >> 34916675

[Methylation status and expression of TWEAK gene promoter region in peripheral blood of patients with rheumatoid arthritis].

X Lou1, L Liao1, X J Li1, N Wang1, S Liu1, R M Cui1, J Xu1.   

Abstract

OBJECTIVE: To explore the relationship between tumor necrosis factor like weak inducer of apoptosis (TWEAK) gene and the pathogenesis of rheumatoid arthritis (RA) by detecting the DNA methylation level, mRNA expression level and serum protein concentration of TWEAK gene in peripheral blood.
METHODS: The MassARRAY method was used to detect the DNA methylation level of the TWEAK gene in the peripheral blood of 112 RA patients and 86 matched healthy volunteers. The real-time quantitative polymerase chain reaction method was used to detect the mRNA expression level of the TWEAK gene in the peripheral blood of the subjects. The enzyme-linked immunosorbent assay method was used to detect the serum TWEAK protein concentration of the subjects. The TWEAK gene DNA methylation level, mRNA expression level and serum protein concentration between the RA group and the healthy control group were compared, and the relationship between it and the degree of disease activity analyzed.
RESULTS: The overall DNA methylation level of TWEAK gene and the DNA methylation levels of CpG_11, CpG_17.18.19.20, CpG_40.41.42 site in the RA group were higher than those in the healthy control group (P=0.002, P=0.01, P=0.006, P=0.002, respectively). The DNA methylation level of CpG_55.56 site in the high disease activity group was higher than that in the medium and low disease activity group (P=0.041). The expression level of TWEAK gene mRNA in the peripheral blood of the RA group was lower than that of the healthy control group (P=0.023). The expression level of TWEAK gene mRNA in the high disease activity group was lower than that in the medium and low disease activity group (P=0.035). The serum TWEAK protein concentration of the RA group was not significantly different from that of the healthy control group (P=0.508), but it was positively correlated with the mRNA expression level (r=0.482, P < 0.001).
CONCLUSION: The TWEAK gene is closely related to the onset and progression of RA, and its hypermethylation state may be one of the epigenetic mechanisms regulating its low mRNA expression, and it can be used as one of the important indicators for clinical monitoring and evaluation of RA.

Entities:  

Keywords:  DNA methylation; Rheumatoid arthritis; Tumor necrosis factor-like weak inducer of apoptosis; mRNA

Mesh:

Substances:

Year:  2021        PMID: 34916675      PMCID: PMC8695153     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  20 in total

1.  TWEAK attenuates the transition from innate to adaptive immunity.

Authors:  Heather Maecker; Eugene Varfolomeev; Frank Kischkel; David Lawrence; Heidi LeBlanc; Wyne Lee; Stephen Hurst; Dimitry Danilenko; Jun Li; Ellen Filvaroff; Becky Yang; Dylan Daniel; Avi Ashkenazi
Journal:  Cell       Date:  2005-12-02       Impact factor: 41.582

Review 2.  Epigenetics in rheumatoid arthritis; fibroblast-like synoviocytes as an emerging paradigm in the pathogenesis of the disease.

Authors:  Jafar Karami; Saeed Aslani; Mohammad Naghi Tahmasebi; Mohammad Javad Mousavi; Arash Sharafat Vaziri; Ahmadreza Jamshidi; Elham Farhadi; Mahdi Mahmoudi
Journal:  Immunol Cell Biol       Date:  2020-01-26       Impact factor: 5.126

Review 3.  [Interleukins network in rheumatoid arthritis pathophysiology: beyond proinflammatory cytokines].

Authors:  Silvia Sánchez-Ramón; Francisco Javier López-Longo; Luis Carreño
Journal:  Reumatol Clin       Date:  2011-03-23

Review 4.  Role of the TWEAK/Fn14 pathway in autoimmune diseases.

Authors:  Wang-Dong Xu; Yi Zhao; Yi Liu
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 5.  Evolving concepts of rheumatoid arthritis.

Authors:  Gary S Firestein
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

6.  Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.

Authors:  M-C Park; S J Chung; S-J Jung; Y-B Park; S-K Lee
Journal:  Scand J Rheumatol       Date:  2008 May-Jun       Impact factor: 3.641

7.  Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells.

Authors:  Hong Zhu; Long-Fei Wu; Xing-Bo Mo; Xin Lu; Hui Tang; Xiao-Wei Zhu; Wei Xia; Yu-Fan Guo; Ming-Jun Wang; Ke-Qin Zeng; Jian Wu; Ying-Hua Qiu; Xiang Lin; Yong-Hong Zhang; Yao-Zhong Liu; Neng-Jun Yi; Fei-Yan Deng; Shu-Feng Lei
Journal:  Ann Rheum Dis       Date:  2018-10-08       Impact factor: 19.103

8.  Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies.

Authors:  Yves Chicheportiche; Rachel Chicheportiche; Irene Sizing; Jeff Thompson; Christopher B Benjamin; Christine Ambrose; Jean-Michel Dayer
Journal:  Arthritis Res       Date:  2001-11-09

9.  TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade.

Authors:  A W R van Kuijk; C A Wijbrandts; M Vinkenoog; T S Zheng; K A Reedquist; P P Tak
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

10.  Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

Authors:  Noa Schwartz; Tamar Rubinstein; Linda C Burkly; Christopher E Collins; Irene Blanco; Lihe Su; Bernard Hojaili; Meggan Mackay; Cynthia Aranow; William Stohl; Brad H Rovin; Jennifer S Michaelson; Chaim Putterman
Journal:  Arthritis Res Ther       Date:  2009-09-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.